The role of thyroid hormones in the regulation of the angiogenesis and cells proliferations



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A series of reports about pro-angiogenic and procancerogenic
activity of thyroids hormones (TH) and its
analogues sold through nongenomic action. The nongenomic
actions of TH require a plasma membrane receptor or nuclear
receptors located in cytoplasm. The plasma membrane
receptor is located on integrin бVв3 at the Arg-Gly-Asp
recognition site important to the binding by the integrin
of extracellular matrix proteins. TH differ in their ability to
influence the бVв3: L-thyroxine (T4), linking through the main
site of the receptor, it activates mainly mitogen-activated
protein kinase (MAPK; ERK1/2) and 3,5,3-triiodo-L-thyronine
(T3) binding by other site affects to phosphatidylinositol-3-
kinase (PI-3-K). This messengers transduce the hormone
signal into complex cellular/nuclear events including increased
expression of basic fibroblast growth factor (bFGF), vascular
endothelial growth factor (VEGF), hypoxia-induced factor 1-б
(HIF-1б) and consequent leads to activation of angiogenesis
and cell proliferation. Treatment of cell with thyroid
hormones caused expression of inflammation-associated
genes: cyclooxygenase-2, matrix metalloproteinase-9.
Tetraiodothyroacetic (tetrac) blocks thyroid hormone effects
on angiogenesis and cancer cell proliferation.

About the authors

R I Glushakov

State Pediatric Medical Academy, Saint-Petersburg

State Pediatric Medical Academy, Saint-Petersburg

S N Proshin

Northwestern Medical University n.a. I.I. Mechnikov, Saint-Petersburg

Northwestern Medical University n.a. I.I. Mechnikov, Saint-Petersburg

N I Tapilskaya

State Pediatric Medical Academy, Saint-Petersburg

State Pediatric Medical Academy, Saint-Petersburg

References

  1. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Фун- даментальная и клиническая тироидология. М.: Медицина; 2007: 816.
  2. Ness R.B., Grisso J.A., Cottreau C. et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000; 11: 111-17.
  3. Shering S.G., Zbar A.P., Moriarty M. et al. Thyroid disorders and breast cancer. Eur. J. Cancer. Prev. 1996; 5(6): 504-6.
  4. Angelousi A.G., Anagnostou V.K., Stamatakos M.K. et al. Primary Hypothyroidism and Risk for Breast Cancer: A Systematic Review and Meta-Analysis. Eur. J. Endocrinol. 2011; EJE-11-0838 (http://eje-online.org).
  5. Davis P.J., Leonard J.L., Davis F.B. Mechanisms of nongenomic actions of thyroid hormone. Frontiers in Neuroendocrinology. 2008; 29: 211-18.
  6. Lin H.-Y., Sun M., Tang H.-Y. et al. L-Thyroxine vs. 3,5,3'-triiodo- L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol-3-kinase, Am. J. Physiol. Cell Physiol. 2009; 296: 980-91.
  7. Davis P.J., Shih A., Lin H.-Y. et al. Thyroxine promotes association of mitogen-activated protein kinase and nuclear thyroid hormone receptor (TR) and causes serine phosphorylation of TR. J. Biol. Chem. 2000; 275: 38032-39.
  8. Davis P.J., Davis F.B., Mousa S.A. et al. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu. Rev. Pharmacol. Toxicol. 2011; 51: 99-115.
  9. Davis F.B., Tang H.-Y., Shih A. et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res. 2006; 66(14): 7270-5.
  10. Lin H.Y., Tang H.Y., Shih A. et al. Thyroid hormone is a MAPKdependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007; 72: 180-7.
  11. Tomanek R.J., Doty M.K., Sandra A. Early coronary angiogenesis in response to thyroxine. Growth characteristics and upregulation of basic fibroblast growth factor. Circ. Res. 1998; 82: 587-93.
  12. Tomanek R.J., Busch T.L. Coordinated capillary and myocardial growth in response to thyroxine treatment. Anat. Rec. 1998; 251: 44-9.
  13. Barreto-Chaves M.L., de Souza Monteiro P., Fürstenau C.R. Acute actions of thyroid hormone on blood vessel biochemistry and physiology. Curr. Opin. Endocrinol. Diabetes. Obes. 2011; 18(5): 300-3.
  14. Wang X., Zheng W., Christensen L.P. et al. DITPA stimulates bFGF, VEGF, angiopoietin, and Tie-2 and facilitates coronary arteriolar growth. Am. J. Physiol. 2003; 284: 613-8.
  15. Kuzman J.A., Tang Y., Vogelsang K.A. et al. Thyroid hormone analog, diiodothyropropionic acid (DITPA), exerts beneficial effects on chamber and cellular remodeling in cardiomyopathic hamsters. Can. J. Physiol. Pharmacol. 2007; 85: 3121-318.
  16. Schlenker E.H., Hora M., Liu Y. et al. Effects of thyroidectomy, T4, and DITPA replacement on brain blood vessel density in adult rats. Am. J. Physiol. 2008; 294: 1504-9.
  17. Liu Y., Redetzke R.A., Said S. et al. Serum thyroid hormone levels may not accurately reflect thyroid tissue levels and cardiac function in mild hypothyroidism. Am. J. Physiol. 2008; 294: 2137-42.
  18. Fazio S., Palmieri E.A., Lombardi G., et al. Effects of thyroid hormone on the cardiovascular system. Recent. Prog. Horm. Res. 2004; 59: 31-50.
  19. Pingitore A., Galli E., Barison A., et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebocontrolled study. J. Clin. Endocrinol. Metab. 2008; 93: 1351-8
  20. Davis P.J., Lin H.Y., Mousa S.A. et al. Overlapping nongenomic and genomic actions of thyroid hormone and steroids. Steroids 2011; 76 (9): 829-33.
  21. Hercbergs A.A., Goyal L.K., Suh J.H. et al. Propylthiouracilinduced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a Phase I/II study. Anticancer. Res. 2003; 23: 617-26.
  22. Linetsky E., Hercbergs A.A., Dotan S. et al. Time to tumor progression (TTP) and quality of life (QOL) following propylthiouracil induction of chemical hypothyroidism in failed malignant gliomas. Proceedings of the Second Quadrennial Meeting of the World Federation of Neurooncology. 2005; 7(3): 318.
  23. Cohen K., Ellis M., Khoury S. et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via αvβ3 integrin. Mol. Cancer Res. 2011; 9(10): 1385-94.
  24. Cristofanilli M., Yamamura Y., Kau S.W., et al. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005; 103: 1122-8.
  25. Hercbergs A.H., Ashur-Fabian O., Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr. Opin. Endocrinol. Diabetes. Obes. 2010; 17(5): 432-6
  26. Davis P.J., Davis F.B., Mousa S.A. Thyroid hormone induced angiogenesis. Current Cardiol. Rev. 2009; 5: 12-6.
  27. Lin H.Y., Cody V., Davis F.B. et al. Identification and functions of the plasma membrane receptor for thyroid hormone analogues. Discov. Med. 2011; 11(59): 337-47.
  28. Glinskii A.B., Glinsky G.V., Lin H.-Y. et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009; 8(21): 3562-70.
  29. Shih C., Chen S., Yen C. et al. Thyroid hormone receptordependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinol. 2004; 145: 2804-14.
  30. Yalcin M., Bharali D.J., Lansing L. et al. Tetraidothyroacetic acid (Tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009; 29 (10): 3825-31.
  31. Yalcin M., Dyskin E., Lansing L. et al. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J. Clin. Endocrinol. Metab. 2010; 95(4): 1972-80.
  32. Moeller L. C., Dumitrescu A. M., Refetoff S. Cytosolic action of thyroid hormone leads to induction of hypoxia-inducible factor-1- alpha and glycolytic genes. Mol. Endocrinol. 2005; 19: 2955-63.
  33. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxiainducible factor 1. Critical Reviews in oncology/hematology. 2006; 59: 15-26.
  34. Faivre-Sarrailh C., Rabie A. A lower proportion of filamentous to monomeric actin in the developing cerebellum of thyroid-deficient rats. Brain Res. 1988; 469: 293-7.
  35. Farwell A.P., Dubord-Tomasetti S.A., Pietrzykowski A.Z., Leonard J.L. Regulation of cerebellar neuronal migration and neurite outgrowth by thyroxine and 3,3',5'-triiodothyronine. Brain Res. Dev. Brain Res. 2005; 154: 121-35.
  36. Siegrist-Kaiser C.A., Juge-Aubry C., Tranter M.P. et al. Thyroxine-dependent modulation of actin polymerization in cultured astrocytes. A novel extranuclear action of thyroid hormone. J. Biol. Chem. 1990; 265: 5296-302
  37. Rae M. T., Gubbay O., Kostogiannou A. et al. Thyroid hormone signaling in human ovarian surface epithelial cells. J. Clin. Endocrinol. Metab. 2007; 92(1): 322-7.
  38. Nicosia S.V., Bai W., Cheng J.Q., et al. Oncogenic pathways implicated in ovarian epithelial cancer. Hematol. Oncol. Clin. North. Am. 2003; 17: 927-43.
  39. Garfield D.H., Wolter P., Schöffski P. et al. Documentation of Thyroid Function in Clinical Studies With Sunitinib: Why Does It Matter? J. Clin. Oncol. 2008; 26 (31): 5131-3.
  40. Furuya F., Hanover J.A., Cheng S.Y. Activation of phosphatidylinositol-3-kinase signaling by a mutant thyroid hormone beta receptor. PNAS USA 2006; 103: 1780-5.
  41. Rosen M.D., Chan I.H., Privalsky M.L. Mutant thyroid hormone receptors (TRs) isolated from distinct cancer types display distinct target gene specificities: a unique regulatory repertoire associated with two renal clear cell carcinomas. Mol. Endocrinol. 2011; 25(8): 1311-25.
  42. Krassas G.E. Thyroid disease and female reproduction. Fertil. Steril. 2000; 74(6): 1063-70.
  43. Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol. Oncol. 2000; 77(3): 369-76.
  44. Hara I., Miyake H., Hara S. et al. Clinical outcome of radical cystectomy for patients with pT4 bladder cancer. Int. J. Urol. 2001; 165 (5): 1769-72.
  45. Dombrowski F., Klotz L., Hacker H. J. et al. Hyperproliferative hepatocellular alterations after intraportal transplantation of thyroid follicles. Am. J. Pathol. 2000; 156: 99-113.
  46. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell. 2005; 7: 211-7.
  47. Stolina M., Sharma S., Lyn Y. et al. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL -12 synthesis. J. Immunol. 2000; 164: 361-70. 43. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized
  48. Tsujii M., Kawano S., Tsuji S. et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998; 93: 705-16.
  49. Voutsadakis I.A. Pathogenesis of colorectal carcinoma and therapeutic implications: roles of ubiquitin-proteasome system and COX-2. J. Cell Mol. Med. 2007; 11: 252-85.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies